This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial
Williamson, Jeff D.,
Launer, Lenore J.,
Bryan, R. Nick,
Coker, Laura H.,
Lazar, Ronald M.,
Gerstein, Hertzel C.,
Murray, Anne M.,
Sullivan, Mark D.,
Horowitz, Karen R.,
Ding, Jingzhong,
Marcovina, Santica,
Lovato, Laura,
Lovato, James,
Margolis, Karen L.,
Davatzikos, Christos,
Barzilay, Joshua,
Ginsberg, Henry N.,
Linz, Peter E.,
Miller, Michael E.
Importance: Persons with type 2 diabetes mellitus (T2DM) are at increased risk for decline in cognitive function, reduced brain volume, and increased white matter lesions in the brain. Poor control of blood pressure (BP) and lipid levels are risk factors for T2DM-related cognitive decline, but the effect of intensive treatment on brain function and structure […]
The long-term efficacy and tolerability of donepezil in patients with vascular dementia
Wilkinson, David,
Róman, Gustavo,
Salloway, Stephen,
Hecker, Jane,
Boundy, Karyn,
Kumar, Dinesh,
Posner, Holly,
Schindler, Rachel
Objective: To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD).; Methods: International, multicentre, open-label, 30-week extension study of two 24-week, randomised, double-blind, placebo-controlled studies. Participants were ambulatory adults (59% female; mean age, 74.7 +/- 0.3) with a diagnosis of possible or probable VaD and without a diagnosis of Alzheimer’s […]
Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
Background: A varying response to cholinesterase inhibitor (ChEI) treatment has been reported among patients with Alzheimer’s disease (AD). Whether the individual-specific response, specific ChEI agent or dose affects mortality is unclear. We aimed to examine the relationship between the 6-month response to ChEI and lifespan. Methods: Six hundred and eighty-one deceased patients with a clinical […]
Memantine in behavioral variant frontotemporal dementia: negative results
Vercelletto, Martine,
Boutoleau-Bretonnière, Claire,
Volteau, Christelle,
Puel, Michèle,
Auriacombe, Sophie,
Sarazin, Marie,
Michel, Bernard-François,
Couratier, Philippe,
Thomas-Antérion, Catherine,
Verpillat, Patrice,
Gabelle, Audrey,
Golfier, Véronique,
Cerato, Evelyne,
Lacomblez, Lucette
We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD). BvFTD patients aged 45 to 75 years, with a Mini-Mental Status Examination (MMSE) score ≥19, were enrolled in a national, randomized, double-blind, placebo-controlled (DBPC), Phase II trial. The primary endpoint was the CIBIC-Plus (Clinician’s Interview-Based […]
Effects of small-scale, home-like facilities in dementia care on residents’ behavior, and use of physical restraints and psychotropic drugs: A quasi-experimental study
Verbeek, Hilde,
Zwakhalen, Sandra M.G.,
van Rossum, Erik,
Ambergen, Ton,
Kempen, Gertrudis I.J.M.,
Hamers, Jan P.H.
Background: Small-scale, home-like care environments are increasingly implemented in institutional nursing care as a model to promote resident-directed care, although evidence on its effects is sparse. This study focuses on the effects of small-scale living facilities on the behavior of residents with dementia and use of physical restraints and psychotropic drugs. Methods: A quasi-experimental study […]
EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study
Vellas, B.,
Sol, O.,
Snyder, P. J.,
Ousset, P. J.,
Haddad, R.,
Maurin, M.,
Lemarié, J. C.,
Désiré, L.,
Pando, M. P.
Background: EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer’s Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.; Methods: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in […]
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial
Vellas, Bruno,
Coley, Nicola,
Ousset, Pierre-Jean,
Berrut, Gilles,
Dartigues, Jean-François,
Dubois, Bruno,
Grandjean, Hélène,
Pasquier, Florence,
Piette, François,
Robert, Philippe,
Touchon, Jacques,
Garnier, Philippe,
Mathiex-Fortunet, Hélène,
Andrieu, Sandrine
Background: Prevention strategies are urgently needed to tackle the growing burden of Alzheimer’s disease. We aimed to assess efficacy of long-term use of standardised ginkgo biloba extract for the reduction of incidence of Alzheimer’s disease in elderly adults with memory complaints.; Methods: In the randomised, parallel-group, double-blind, placebo-controlled GuidAge clinical trial, we enrolled adults aged […]